The “personalized molecular surgery” expression plasmid can be packaged into a virus and delivered intratracheally or intravascularly to patients.76 Based on the mechanism analysis of drug resistance in breast cancer, a similar strategy could also be used in ER or HER2 mutants in patients with breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.